NIH R01 · 2024
PROJECT SUMMARY More than 12 million Americans currently live with both obesity and type 2 diabetes (T2D), putting them in one of the highest risk groups for developing serious microvascular and macrovascular complications. The Ameri- can Diabetes Association’s clinical practice guidelines recommend metabolic/bariatric surgery (MBS) and/or pharmacologic treatment of obesity for patients with obesity and T2D. In particular, glucagon-like peptide-1 re- ceptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) have both demonstrated efficacy in weight loss and preventing microvascular and macrovascular complications and are more accessi- ble than MBS. However, there…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.